Lynparza plus abi/pred approved in Japan for treatment of prostate cancer
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
Rs. 64000 crores are being invested across the 750 districts of India, to create a more resilient healthcare system in the country
The company has entered into a three-year Deferred Prosecution Agreement
The drug will be manufactured at JB Pharma's formulation manufacturing facility in Panoli, Gujarat
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Mizoram appoints Youth for Action as the Interfacing Agency for implementing the ABDM Microsite in Aizawl
Guaifenesin extended-release tablets help to loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive
Eris Lifesciences enters into term loan agreement with Citi Bank
Jupiter has filed its draft herring prospectus (DRHP) with the market regulator in May this year, to float its IPO
Weinand is the former CEO and Chairman of the Board at Bayer Pharma AG, leading Bayer’s fully integrated $20 billion healthcare business
Subscribe To Our Newsletter & Stay Updated